G Dickneite

Summary

Affiliation: CSL Behring GmbH
Country: Switzerland

Publications

  1. ncbi request reprint Wound healing and degradation of the fibrin sealant Beriplast P following partial liver resection in rabbits
    Monika Kroez
    ZLB Behring GmbH, Marburg, Germany
    Wound Repair Regen 13:318-23. 2005
  2. doi request reprint Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model
    Gerhard Dickneite
    Department of Pharmacology and Toxicology, CSL Behring GmbH, Marburg, Germany
    J Trauma 68:1151-7. 2010
  3. pmc Prothrombin complex concentrate mitigates diffuse bleeding after cardiopulmonary bypass in a porcine model
    F Kaspereit
    Department of Preclinical Research and Development, CSL Behring GmbH, Marburg, Germany
    Br J Anaesth 105:576-82. 2010
  4. doi request reprint Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?
    Gerhard Dickneite
    Prof Dr Gerhard Dickneite, Preclinical R and D, CSL Behring, PO Box 1230, 35002 Marburg, Germany, Tel 49 6421 39 2306, Fax 49 6421 39 4663, E mail
    Thromb Haemost 111:189-98. 2014
  5. doi request reprint Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P)
    Gerhard Dickneite
    Department of Pharmacology and Toxicology, CSL Behring GmbH, Emil von Behring Strasse 76, D 35041 Marburg, Germany
    Blood Coagul Fibrinolysis 20:535-40. 2009
  6. pmc Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model
    G Dickneite
    Department of Pharmacology and Toxicology, CSL Behring GmbH, Marburg, Germany
    Br J Anaesth 102:345-54. 2009
  7. doi request reprint A comparison of the pharmacokinetics of antithrombin derived from human plasma and from transgenic goats and the prevention of sepsis in an animal model
    Gerhard Dickneite
    Department of Pharmacology and Toxicology, CSL Behring GmbH, Marburg, Germany
    Biopharm Drug Dispos 29:356-65. 2008
  8. doi request reprint Characterization of the coagulation deficit in porcine dilutional coagulopathy and substitution with a prothrombin complex concentrate
    Gerhard Dickneite
    Department of Pharmacology and Toxicology, CSL Behring GmbH, Marburg, Germany
    Anesth Analg 106:1070-7, table of contents. 2008
  9. doi request reprint Prothrombin complex concentrate (Beriplex P/N) for control of bleeding after kidney trauma in a rabbit dilutional coagulopathy model
    Ingo Pragst
    Department of Pharmacology and Toxicology, CSL Behring GmbH, Marburg, Germany
    Thromb Res 125:272-7. 2010
  10. doi request reprint Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model
    E Raquet
    Departments of Preclinical Research and Development Medical Affairs, Commercial Development Coagulation, CSL Behring GmbH, Marburg, Germany
    Haemophilia 17:808-14. 2011

Collaborators

Detail Information

Publications22

  1. ncbi request reprint Wound healing and degradation of the fibrin sealant Beriplast P following partial liver resection in rabbits
    Monika Kroez
    ZLB Behring GmbH, Marburg, Germany
    Wound Repair Regen 13:318-23. 2005
    ..In humans, the reduced immunogenicity of the FS would potentially increase its degradation half-life...
  2. doi request reprint Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model
    Gerhard Dickneite
    Department of Pharmacology and Toxicology, CSL Behring GmbH, Marburg, Germany
    J Trauma 68:1151-7. 2010
    ..Multicomponent therapy with prothrombin complex concentrate (PCC) containing coagulation factors II, VII, IX, and X might offer potential advantages...
  3. pmc Prothrombin complex concentrate mitigates diffuse bleeding after cardiopulmonary bypass in a porcine model
    F Kaspereit
    Department of Preclinical Research and Development, CSL Behring GmbH, Marburg, Germany
    Br J Anaesth 105:576-82. 2010
    ..Prothrombin complex concentrate (PCC) containing clotting factors II (FII), VII (FVII), IX (FIX), and X (FX) could be of potential value in correcting dilutional coagulopathy and reducing blood loss...
  4. doi request reprint Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?
    Gerhard Dickneite
    Prof Dr Gerhard Dickneite, Preclinical R and D, CSL Behring, PO Box 1230, 35002 Marburg, Germany, Tel 49 6421 39 2306, Fax 49 6421 39 4663, E mail
    Thromb Haemost 111:189-98. 2014
    ..According to the current evidence, use of PCCs may be considered a reasonable approach in dire clinical situations; however, a consensus has not yet been reached regarding PCC use or dosing, due to lack of clinical data...
  5. doi request reprint Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P)
    Gerhard Dickneite
    Department of Pharmacology and Toxicology, CSL Behring GmbH, Emil von Behring Strasse 76, D 35041 Marburg, Germany
    Blood Coagul Fibrinolysis 20:535-40. 2009
    ..Evidence from an animal model of venous stasis, a comprehensive pharmacosurveillance program, and a systematic review of clinical studies indicates that the thrombogenic potential of fibrinogen concentrate is low...
  6. pmc Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model
    G Dickneite
    Department of Pharmacology and Toxicology, CSL Behring GmbH, Marburg, Germany
    Br J Anaesth 102:345-54. 2009
    ..Compared with fresh frozen plasma (FFP), prothrombin complex concentrate (PCC) may potentially offer a more rapid and effective means of normalizing coagulation factor levels...
  7. doi request reprint A comparison of the pharmacokinetics of antithrombin derived from human plasma and from transgenic goats and the prevention of sepsis in an animal model
    Gerhard Dickneite
    Department of Pharmacology and Toxicology, CSL Behring GmbH, Marburg, Germany
    Biopharm Drug Dispos 29:356-65. 2008
    ..99-1.86). HpAT and tgAT have differing pharmacokinetic properties in pre-clinical studies. Further research is necessary to establish whether this translates into efficacy differences in vivo and in the clinical therapy of sepsis...
  8. doi request reprint Characterization of the coagulation deficit in porcine dilutional coagulopathy and substitution with a prothrombin complex concentrate
    Gerhard Dickneite
    Department of Pharmacology and Toxicology, CSL Behring GmbH, Marburg, Germany
    Anesth Analg 106:1070-7, table of contents. 2008
    ....
  9. doi request reprint Prothrombin complex concentrate (Beriplex P/N) for control of bleeding after kidney trauma in a rabbit dilutional coagulopathy model
    Ingo Pragst
    Department of Pharmacology and Toxicology, CSL Behring GmbH, Marburg, Germany
    Thromb Res 125:272-7. 2010
    ....
  10. doi request reprint Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model
    E Raquet
    Departments of Preclinical Research and Development Medical Affairs, Commercial Development Coagulation, CSL Behring GmbH, Marburg, Germany
    Haemophilia 17:808-14. 2011
    ..Half-life did not differ between the two concentrates. Animal model data suggest that exposure to elevated FVIII levels can be reduced through use of VWF/FVIII concentrates with higher VWF:FVIII ratios...
  11. doi request reprint Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model
    I Pragst
    CSL Behring GmbH, Marburg Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    J Thromb Haemost 10:1841-8. 2012
    ..Prothrombin complex concentrates (PCCs) have served as a standard treatment for the reversal of coumarin anticoagulation...
  12. ncbi request reprint Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig
    G Dickneite
    Research Laboratories of Centeon Pharma GmbH, Marburg, Germany
    Thromb Haemost 80:192-8. 1998
    ..No effect on either aPTT nor rH plasma levels were observed with any of the study drugs. It was concluded that Haemate decreases excess bleeding induced by rH/aspirin treatment without altering rH's anticoagulant effect...
  13. ncbi request reprint Treatment of porcine sepsis with high-dose antithrombin III reduces tissue edema and effusion but does not increase risk for bleeding
    G Dickneite
    Pharmacology and Toxicology, Aventis Behring GmbH, Marburg, Germany
    Blood Coagul Fibrinolysis 12:459-67. 2001
    ....
  14. ncbi request reprint Prevention of gynaecological adhesions using haemostatic fleece in a rabbit model
    G Dickneite
    ZLB Behring GmbH, Marburg, Germany
    J Int Med Res 34:505-13. 2006
    ..4 versus 2.0) with TachoComb than in the control group. This study indicates that TachoComb is a well-tolerated and effective means of preventing adhesion following gynaecological surgery...
  15. doi request reprint Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs
    M W Nolte
    Preclinical Research and Development, CSL Behring GmbH, Marburg, Germany
    J Thromb Haemost 10:1591-9. 2012
    ..A FIX molecule with a prolonged half-life has the potential to greatly improve the convenience of, and adherence to, prophylaxis...
  16. ncbi request reprint The importance of factor XIII as a component of fibrin sealants
    Gerhard Dickneite
    Aventis Behring GmbH, D 35002, Marburg, Germany
    J Surg Res 107:186-95. 2002
    ..Some commercially available fibrin sealants (FS) contain high levels of FXIII (up to 70-80 U/mL) while others contain low levels or none. The objective of the present studies was to investigate the need for FXIII in FS...
  17. ncbi request reprint Targeted inactivation of the mouse locus encoding coagulation factor XIII-A: hemostatic abnormalities in mutant mice and characterization of the coagulation deficit
    Peter Lauer
    Aventis Behring GmbH, Pharmacology Toxicology, Marburg, Germany
    Thromb Haemost 88:967-74. 2002
    ..The mutant mice thus reiterate some key features of the human genetic disorder: they will be valuable in assessing the role of FXIII in other associated pathologies and the development of new therapies...
  18. ncbi request reprint The effect of fibrinogen concentrate administration on coagulation abnormalities in a rat sepsis model
    Franz Kaspereit
    Aventis Behring GmbH, Pharmacology Toxicology, Marburg, Germany
    Blood Coagul Fibrinolysis 15:39-43. 2004
    ..A significant decrease in sepsis-induced mortality was observed in animals treated with Haemocomplettan P...
  19. ncbi request reprint Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation
    Gerhard Dickneite
    ZLB Behring GmbH, D 35002 Marburg, Germany
    Thromb Res 119:643-51. 2007
    ..This study was designed to compare the effectiveness of PCC and rFVIIa for reversal of both acute and sustained coumarin anticoagulation...
  20. ncbi request reprint C1-inhibitor for prophylaxis of xenograft rejection after pig to cynomolgus monkey kidney transplantation
    Jens M Hecker
    Klinik für Viszeral und Transplantationschirurgie, Zentrum Anasthesiologie, Institut fur Pathologie, Medizinische Hochschule Hannover, Hannover, Germany
    Transplantation 73:688-94. 2002
    ....
  21. ncbi request reprint Factor XIII A subunit-deficient mice developed severe uterine bleeding events and subsequent spontaneous miscarriages
    Shiori Koseki-Kuno
    Department of Molecular Patho Biochemistry and Patho Biology, Yamagata University School of Medicine, Iida nishi 2 2 2, Yamagata 990 9585 Japan
    Blood 102:4410-2. 2003
    ..These results are reminiscent of spontaneous miscarriage in pregnant humans with FXIII deficiency and indicate that maternal FXIII plays a critical role in uterine hemostasis and maintenance of the placenta during gestation...
  22. ncbi request reprint A comparison of fibrin sealants in relation to their in vitro and in vivo properties
    Gerhard Dickneite
    Pharmacology and Toxicology, Aventis Behring, P O Box 1230, D 35002 Marburg, Germany
    Thromb Res 112:73-82. 2003
    ..While their composition is similar, different formulations, application devices, and varying concentrations of key components mean that the properties of clots formed by individual FS can be diverse...